Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Limited is engaged in the marketing of pharmaceutical products in domestic and international markets. The company is also engaged in distribution of pharmaceutical products through third-party distribution network.[1]It is a part of the Trident Texofab Group
- Market Cap ₹ 182 Cr.
- Current Price ₹ 158
- High / Low ₹ 240 / 128
- Stock P/E 30.6
- Book Value ₹ 46.0
- Dividend Yield 0.00 %
- ROCE 18.1 %
- ROE 13.0 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.55%
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 21.77 | 31.69 | 44.63 | |
| 19.05 | 25.43 | 36.45 | |
| Operating Profit | 2.72 | 6.26 | 8.18 |
| OPM % | 12.49% | 19.75% | 18.33% |
| 0.60 | 1.16 | 2.08 | |
| Interest | 0.13 | 0.48 | 0.60 |
| Depreciation | 0.20 | 0.36 | 0.97 |
| Profit before tax | 2.99 | 6.58 | 8.69 |
| Tax % | -32.11% | 8.51% | 31.65% |
| 3.95 | 6.02 | 5.94 | |
| EPS in Rs | 4.94 | 5.24 | 5.51 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 41% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 8.00 | 11.50 | 11.50 |
| Reserves | -3.22 | 34.14 | 41.40 |
| 2.46 | 5.58 | 18.41 | |
| 6.60 | 7.63 | 15.77 | |
| Total Liabilities | 13.84 | 58.85 | 87.08 |
| 1.43 | 3.11 | 20.90 | |
| CWIP | 0.00 | 2.60 | 4.03 |
| Investments | 0.00 | 2.93 | 3.77 |
| 12.41 | 50.21 | 58.38 | |
| Total Assets | 13.84 | 58.85 | 87.08 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| -0.21 | -17.44 | 2.23 | |
| -0.45 | -6.94 | -20.36 | |
| 0.80 | 38.00 | 11.01 | |
| Net Cash Flow | 0.14 | 13.62 | -7.13 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 83.33 | 139.60 | |
| Inventory Days | 95.16 | 129.36 | |
| Days Payable | 134.15 | 86.96 | |
| Cash Conversion Cycle | 44.34 | 182.00 | |
| Working Capital Days | 66.56 | 313.52 | |
| ROCE % | 24.15% |
Documents
Announcements
- Intimation Of Change Of Holding In TLL PARENTERALS LIMITED (CIN: U21001GJ2023PLC146963)(Subsidiary Company). 2d
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
1 May - Mr. Jiteshkumar R Varkal (Membership No. ACS 31727) has tendered his resignation from the post of Company Secretary & Compliance Officer of the Company with …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
1 May - Earnings Presentation for the half year and year ended 31st March, 2024 (H2FY24).
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 Apr - Read with Schedule III Part A Para A and Regulation 47 of SEBI Listing Regulations, we hereby enclose copies of newspaper advertisement published on, 29th …
- Statement Of Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (LODR) Regulations, 2015 27 Apr
Business categories[1]
1. Ethical marketing of pharmaceutical formulation & products in International Markets through a third-party distribution network and sales force under its own brand
2. Getting approved formulations manufactured through Contract Manufacturers, Source & Supply of Generic Pharma formulation and medicines in Domestic and International Market.
The company is working on Asset-light third-party contract manufacturing model.